Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 27 Mar 2026. The item focuses on Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors. Review the original article for the full source wording and details.
Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 27 Mar 2026.
The item focuses on Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.
Review the original article for the full source wording and details.